Evaluation of in-house dengue real-time PCR assays in West Java, IndonesiaPublic Health Published on 2024-07-242024-09-05 Journal: PeerJ [Category] update2024, [키워드] Dengue dengue virus NS1 Rapid diagnostic test rRT-PCR serology test West Java [DOI] 10.7717/peerj.17758 PMC 바로가기 [Article Type] Public Health
A review post-vaccination SARS-CoV-2 serological test: Method and antibody titer responseArticle Published on 2022-12-012022-11-15 Journal: Analytical biochemistry [Category] COVID19(2023년), SARS, 진단, [키워드] Antibody titer chemiluminescent immunoassay CLIA CMIA Convalescent plasma therapy Coronavirus disease 2019 COVID-19 Efficacy effort ELISA human donor identify immune response Immune titer immunoassay Lateral LFIA pandemic plaque PRNT reactive SARS-CoV-2 serological serological test Serologist Serologist method serology test Test Vaccine Vaccines [DOI] 10.1016/j.ab.2022.114902 PMC 바로가기
A comparison of conventional and advanced electroanalytical methods to detect SARS-CoV-2 virus: A concise reviewArticle Published on 2022-11-012022-11-15 Journal: Chemosphere [Category] COVID19(2023년), SARS, 치료기술, [키워드] approach approaches Computed tomography COVID-19 COVID-19 disease COVID-19 virus Critical detect detection develop disease electrochemical biosensor equipment identify improvement isothermal amplification Modified electrode outbreak pandemic disease PCR Point point of care polymerase chain polymerase chain reaction Research researcher researchers respiratory SARS-CoV-2 serology test virus virus detection [DOI] 10.1016/j.chemosphere.2022.135645 PMC 바로가기
An impedimetric biosensor for COVID-19 serology test and modification of sensor performance via dielectrophoresis force유전영동력을 통한 센서 성능 수정 및 COVID-19 혈청학 테스트를 위한 방해계 바이오센서Article Published on 2022-10-012022-09-11 Journal: Biosensors & bioelectronics [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-S antibody antibody Antibody detection Antibody test assistance AuNP binding buffer causative agent caused Concentration conjugate coronavirus coronavirus disease Coronavirus disease 2019 COVID COVID-19 COVID-19 antibody COVID-19 serology test described detect Dielectrophoresis force digit faster gold Gold interdigitated electrodes Gold nanoparticles human sera IDE immunization impedance Impedimetric biosensor. limit of detection Modification morbidity and mortality non-specific phenomenon point-of-care solution Protein purified reached responses SARS-CoV-2 secondary antibody sensitivity sensor sera serology serology test serology tests serum severe acute respiratory syndrome Coronavirus Spectroscopy spike the disease therapeutic time-consuming [DOI] 10.1016/j.bios.2022.114476 PMC 바로가기 [Article Type] Article
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjectsArticle Published on 2022-09-292022-11-15 Journal: PLoS ONE [Category] SARS, 변종, 진단, [키워드] antibodies antibody Antigen applied Characteristics Collecting COVID-19 defined determine Dilution dilutions dose doses help humoral Humoral immunity immune response Infection information intensity linear long-lasting MONITOR Pfizer Prevent profile protective immunity quantification quantitative assay RBD reactivity Reinfection Sample SARS-CoV-2 SARS-CoV-2 antigens serological serology test serum sample subject two group vaccination Vaccination strategies Vaccine variant Viral antigen was used were used [DOI] 10.1371/journal.pone.0274553 PMC 바로가기
Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology TestsArticle Published on 2022-09-142022-11-15 Journal: Viruses [Category] SARS, 변종, 진단, 치료기술, [키워드] Adequate Analysis analyzed antibody antibody tests B.1 can be used caused characterized conserved convalescent sera COVID-19 COVID-19 patient cross-reactive cross-reactivity diagnostic domain ELISA test epitope global pandemic Humoral immunity immunogenic Infection magnitude new coronavirus SARS-CoV-2 nucleocapsid Nucleocapsid phosphoprotein patients positive correlation Protein raised RBD Recombinant protein reduced SARS-CoV-2 SARS-CoV-2 strain selective sensitivity sera serology test serology tests spike Spread Test the SARS-CoV-2 Vaccine variants of concern virus VoC VOCs [DOI] 10.3390/v14092041 PMC 바로가기
Vertical transmission and humoral immune response following maternal infection with SARS-CoV-2: a prospective multicenter cohort studyArticle Published on 2022-09-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% confidence interval anti-Nucleocapsid IgG anti-SARS-CoV-2 Anti-spike anti-Spike IgG antibodies antibody Blood conducted COVID-19 declined defined enrolled highest humoral immune response IgG IgM Infection Level mother multicenter cohort study Nasopharyngeal swab Neonatal Neonate Neonates nucleocapsid PCR PCR testing positive positive IgG antibody positive PCR result positive serology Post-infection Pregnancy pregnant women primary endpoint prospective cohort study RT-PCR SARS-CoV-2 SARS-COV-2 infection serology test seronegative seropositive spike IgG tested Transmission transmission of SARS-CoV-2 vertical transmission women [DOI] 10.1016/j.cmi.2022.04.001 PMC 바로가기
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 studyClinical Trial Published on 2022-09-012022-10-05 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95% CI Administered Adults adverse event age all age group antibody baseline Bharat Biodefense children clinical conducted COVID-19 vaccine curtail deaths decrease demonstrated dose Efficacy eight eligible Endpoint enrolled female Fever for inclusion geometric mean GMT ratio GMTs group groups healthy children hospital Hyderabad immunogenicity immunosuppressive inactivated Inactivated vaccine India Infection injection site pain intramuscular dose less Local local reaction male Mild Mild-to-moderate multicentre neutralisation test neutralising antibody response neutralising antibody titre no difference Open-label Pain pandemic participant Phase 2 study phase 2/3 platform positive PRNT Reactions reactogenicity reduction Registered registry reported safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine second dose Serious Adverse Events seroconverted serology test serum sample severity of COVID-19 susceptible Symptom three group titre Trial were excluded Withdrawal [DOI] 10.1016/S1473-3099(22)00307-3 PMC 바로가기 [Article Type] Clinical Trial
Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 vaccine: a prospective cohort studyObservational Study Published on 2022-09-012022-10-05 Journal: Respiratory Research [Category] SARS, 임상, 진단, [키워드] addition age and sex Anti-inflammatory Anti-inflammatory therapy anti-inflammatory treatments Anti-spike antibody Antibody titer antifibrotic therapy BNT162b2 BNT162b2 vaccine caused Cohort conducted control group dose evaluate evaluated healthy control high risk humoral Humoral response ILD immune response Immunosuppression Interstitial lung disease IPF maintain median Messenger RNA Patient patients patients treated patients with ILD prospective cohort study pulmonary fibrosis Rabin Medical Center SARS-CoV-2 vaccine serology test seronegative seropositive Severe COVID-19 Infection significantly lower the healthy therapy treated Treatment vaccination vaccine dose was reduced [DOI] 10.1186/s12931-022-02155-x PMC 바로가기 [Article Type] Observational Study
Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 Among Previously Infected Healthcare Personnel and First Responders중증급성호흡기증후군 코로나바이러스 2로 이전에 감염된 의료진과 응급구조원 중 재감염Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus adjusted hazard ratio antibody association circulation coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 defined exposure to first positive first responders hazard healthcare healthcare personnel household transmission Lower MOST New York City nursing home occurred participant Participants participated positive proportional hazards model Protective provided reduced Reinfection respiratory Responder Rhode Island risk SARS-CoV-2 SARS-CoV-2 test serology test seronegative seropositive seropositive participant seropositive participants Seropositivity serostatus Serosurvey severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spike protein tested variant virus virus test widespread with COVID-19 [DOI] 10.1093/cid/ciab952 PMC 바로가기 [Article Type] Article